NSAID use inversely related to prostate cancer incidence and mortality
Based on a meta-analysis reported in BMC Medicine, NSAID use is associated with a decreased risk of prostate cancer (OR=0.92 [total] and 0.81 [advanced]) and prostate cancer-specific mortality (HR=0.86 [total] and 0.81 [advanced]).
High expression of MUC1 + HER3 is associated with favorable outcome in bladder cancer patients
As reported in BJU International, elevated co-expression of MUC1 + HER3 was associated with improved survival in patients with bladder cancer. MUC1 alone, or elevated MUC1 + non-elevated HER3, had no prognostic value. Moreover, MUC1 was not predictive of survival, tumor stage, or tumor grade.
PCA3 useful for early diagnosis of prostate cancer
Based on a meta-analysis reported in the Chinese Medical Journal, prostate cancer antigen 3 (PCA3) can be used for the early diagnosis of prostate cancer and to avoid unnecessary biopsies, with a sensitivity of 0.82, a specificity of 0.962, a positive likelihood ratio of 2.39, a negative likelihood ratio of 0.51, and a diagnostic odds ratio of 4.89.